Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Asian Cardiovasc Thorac Ann. 2022 Jun;30(5):555-560. doi: 10.1177/02184923211048332. Epub 2021 Sep 23.
Lactated Ringer-based del Nido cardioplegia has been reported to be safe for acquired cardiac surgery. The original Plasma-Lyte-based solution has been proved for congenital cardiac surgery but its modification has not been adequately examined. We compared the clinical outcomes of congenital cardiac surgery using lactated Ringer-based del Nido cardioplegia versus cold blood cardioplegia.
Between September 2018 and November 2020, 116 consecutive patients with congenital heart disease undergoing operations with cardioplegic arrest performed by a single surgeon at Faculty of Medicine Siriraj hospital; 66 with modified del Nido solution and 50 with institutional's blood cardioplegia. The patient risk profiles, operative details, mortality rates, care durations, inotrope use, blood transfusion and complications were compared.
Preoperative characteristics were similar between groups, including median age (2.5 vs. 3.1 years; p = 0.49), size, and gender. The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery score of 3 to 5 was more prevalent in the del Nido group (24.2% vs. 10%; p = 0.049). There were 4 deaths in the modified del Nido group (risk category score of 4) but none in the cold blood group (p = 0.13). There was no significant difference in median intubation duration, length of intensive care unit stay, and vasoactive medications immediately and 24 h after the operation. The del Nido group required 70 to 100 ml less blood transfusion (p = 0.04). All complications were similar between the two groups.
Clinical outcomes of lactated Ringer-based del Nido cardioplegia were comparable to those of blood cardioplegia in congenital cardiac surgery.
基于乳酸林格氏液的 Del Nido 心脏停搏液已被报道可安全用于后天性心脏手术。最初的基于血浆电解质的溶液已被证明可用于先天性心脏手术,但尚未对其改良液进行充分检查。我们比较了使用基于乳酸林格氏液的 Del Nido 心脏停搏液与冷血心脏停搏液进行先天性心脏手术的临床结果。
在 2018 年 9 月至 2020 年 11 月期间,由 Faculty of Medicine Siriraj hospital 的一位外科医生对 116 例接受心脏停搏手术的先天性心脏病患者进行了连续手术;其中 66 例使用改良的 Del Nido 溶液,50 例使用机构的冷血心脏停搏液。比较了两组患者的风险特征、手术细节、死亡率、护理时间、正性肌力药物使用、输血和并发症。
两组患者的术前特征相似,包括中位年龄(2.5 岁与 3.1 岁;p=0.49)、体型和性别。Del Nido 组的胸外科医师协会-欧洲心血管外科学会评分 3 至 5 级更为常见(24.2%与 10%;p=0.049)。改良 Del Nido 组有 4 例死亡(风险类别评分 4 分),而冷血组无死亡(p=0.13)。两组患者的中位插管时间、重症监护病房住院时间和术后即刻及 24 小时的血管活性药物使用无显著差异。Del Nido 组的输血需求减少了 70 至 100ml(p=0.04)。两组患者的所有并发症均相似。
在先天性心脏手术中,基于乳酸林格氏液的 Del Nido 心脏停搏液的临床结果与冷血心脏停搏液相当。